Michael Nally

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018.

MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020.

Harbinger Health, Inc. is a company based in Cambridge, MA. Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis, and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where cancer could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems, and societies. The company fundamentally transforms cancer care for everyone. The company was founded in 2020 by Alexander Meissner, Sidney Farber, Zachary Smith, Franziska Michor. The CEO is Stephen Hahn.